Unlocking the Secrets of Mitochondria in the Cardiovascular System: Path to a Cure in Heart Failure—A Report from the 2018 National Heart, Lung, and Blood Institute Workshop.
E. Douglas Lewandowski, Lisa Schwartz Longacre, Renee Wong, Hilary J. Vernon, Robert G. Weiss, Douglas C. Wallace, Sruti Shiva, Yang Shi, Shey-Shing Sheu, Michael N. Sack, Peipei Ping, Joon-Young Park, Brian O'Rourke, Kevin D. O'Brien, Daria Mochly-Rosen, Joseph M. McClung, Rong Tian, Daniel Levy, Mark J. Kohr, Richard N. Kitsis, Daniel P. Kelly, Roberta A. Gottlieb, Zorina S. Galis, Gerald W. Dorn, Sergey Dikalov, David W. Busija, James E. Bruce, Sihem Boudina, Scott W. Ballinger, Markus M. Bachschmid, Zoltan Arany, Wilson S. Colucci
Journal: Circulation
2020;140(14):1205-1216
PMID: 31769940
Abstract
Mitochondria have emerged as a central factor in the pathogenesis and progression of heart failure, and other cardiovascular diseases, as well, but no therapies are available to treat mitochondrial dysfunction. The National Heart, Lung, and Blood Institute convened a group of leading experts in heart failure, cardiovascular diseases, and mitochondria research in August 2018. These experts reviewed the current state of science and identified key gaps and opportunities in basic, translational, and clinical research focusing on the potential of mitochondria-based therapeutic strategies in heart failure. The workshop provided short- and long-term recommendations for moving the field toward clinical strategies for the prevention and treatment of heart failure and cardiovascular diseases by using mitochondria-based approaches.
© 2019 American Heart Association, Inc.
Address:
Mitochondria and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle.; Department of Medicine, Boston University, MA.; Department of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology, University of Alabama at Birmingham.; Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City.; Department of Genome Sciences, University of Washington, Seattle.; Department of Pharmacology, Tulane University, New Orleans, LA.; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.; Center for Pharmacogenomics, Department of Internal Medicine, Washington University, St. Louis, MO.; National, Heart, Lung, and Blood Institute, National Institutes
of Health, Bethesda, MD.; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.; Department of Medicine, Department of Cell Biology, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY.; Departments of Environmental Health and Engineering, The Johns Hopkins University, Baltimore, MD.; Department of Internal Medicine, The Ohio State University, Columbus.; Department of Physiology, East Carolina University, Greenville, NC.; Department of Chemical and Systems Biology, Stanford University, CA.; Department of Medicine, University of Washington, Seattle.; Department of Medicine, The Johns Hopkins University, Baltimore, MD.; Department of Kinesiology, Temple University, Philadelphia, PA.; Department of Physiology and Department of Medicine, University of California, Los Angeles.; Department of Medicine, Thomas Jefferson University, Philadelphia, PA.; Department of Pharmacology and Chemical Biology and Vascular Medicine Institute, University of Pittsburgh, PA.; Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia Research Institute, PA.; Department of Genetic Medicine, The Johns Hopkins University, Baltimore, MD.
Link outs
Free resources
Full Text Sources:
Medical:
Other Literature Sources:
Subscription / membership required
MeSH Terms:
Biomedical Research,
Cardiovascular System,
Education,
Heart Failure,
Humans,
Mitochondria,
National Heart, Lung, and Blood Institute (U.S.),
Research Report,
Translational Research, Biomedical,
United States